| Competition for tropical disease funding is side-lining critical voices says LSE expert |
|
30/01/2012 05:48 (115 Day 20:55 minutes ago) | |||||
|
The FINANCIAL -- Competition for multi-million pound grants to tackle debilitating parasitic diseases in the developing world means that serious concerns about whether current drug programmes actually work are being side-lined says Professor Tim Allen in a letter published in The Lancet, according to The London School of Economics.
Professor Allen, Professor in Development Anthropology, and Dr Melissa Parker, Director of CRIMA at Brunel University, write that mass drug administration programmes – such as those supported by the UK Government – are often designed without taking into account local political, economic and social issues. They explain that sending vital drugs for neglected tropical diseases, such as bilharzia and elephantiasis, to countries that need them, does not necessarily mean that affected communities in Africa will actually be treated.
Allen and Parker point out that large internationally funded drug distribution programmes can weaken already over-stretched health-care systems.
Professor Allen and Dr Parker also draw attention to medical research which indicates that the long term effects of mass treatment and the combinations of medication to treat multiple infections require much better surveillance and monitoring, particularly when given to already weak and malnourished people.
|
|
|

